Justice Department Can Question Former Elevance Exec in Medicare Advantage Fraud Case, Judge Rules

Why It Matters

The decision deepens federal scrutiny of Medicare Advantage risk‑adjustment practices and could expose Elevance to significant liability, signaling heightened enforcement risk for health insurers.

Key Takeaways

• Judge orders 3.5‑hour deposition of former Elevance exec.
• DOJ alleges $100 million annual overpayments via Medicare Advantage coding.
• Elevance must produce risk‑adjustment revenue forecasts and employee compensation data.
• Former exec claims limited involvement, citing “apex witness” protection.
• Company set aside $935 million for potential Medicare Advantage enrollment suspension.

Pulse Analysis

The Justice Department’s lawsuit against Elevance Health, stemming from its former Anthem identity, centers on alleged manipulation of Medicare Advantage risk‑adjustment data. Prosecutors claim the insurer used a retrospective chart‑review program to add diagnosis codes that inflated payments by more than $100 million per year. By securing a deposition of Peter Haytaian, who oversaw the government business unit during the critical 2012‑2015 period, the DOJ aims to link senior decision‑making directly to the alleged scheme, strengthening its False Claims Act case.

For Elevance, the judge’s order intensifies pressure on an already vulnerable balance sheet. In addition to the deposition, the court mandated the production of detailed revenue forecasts, compensation criteria for 27 risk‑adjustment staff, and board minutes—documents that could reveal the extent of internal knowledge and oversight. Coupled with a $935 million reserve set aside for a separate CMS enrollment dispute, the litigation underscores the financial stakes of compliance failures and may prompt the insurer to accelerate internal reforms and settlement considerations.

The broader implications extend beyond Elevance. As regulators tighten scrutiny of Medicare Advantage risk‑adjustment methodologies, insurers nationwide face heightened exposure to False Claims Act actions. The case highlights the importance of transparent coding practices, robust internal controls, and clear documentation of executive involvement. Stakeholders—from investors to policy makers—will watch closely for how Elevance navigates the discovery process, as its outcome could shape future enforcement priorities and industry standards for Medicare Advantage reporting.